
Nurix Therapeutics Investor Relations Material
Latest events

Study Update
Nurix Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nurix Therapeutics Inc
Access all reports
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule and cell therapies. These therapies are designed to treat cancer and inflammatory diseases by modulating cellular protein levels. Nurix leverages its proprietary DELigase platform, which involves the use of E3 ligases within the ubiquitin-proteasome system, to either decrease or increase protein levels selectively. The company’s drug development strategy includes both targeted protein degraders and ligase inhibitors, addressing unmet medical needs in hematology-oncology, immuno-oncology, and inflammation. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
NRIX
Country
🇺🇸 United States